Health economic impact of patients with phenylketonuria (PKU) in France – A nationwide study of health insurance claims data
The results indicate that PKU is associated with substantially increased health care costs compared to non-PKU controls in France. The health economic impact was most evident in patients with early-diagnosed PKU due to increased outpatient pharmaceutical costs, especially for medical foods including dietary amino acid supplements. For late-diagnosed and by definition older patients with PKU, the excess costs compared with matched controls were mostly driven by costs for inpatient care.
Authors
- Stephane Bouée (ORCID: https://orcid.org/0000-0001-6838-2680)
- Sybil Charrière (ORCID: https://orcid.org/0000-0002-7695-077X)
- Jean‐Baptiste Arnoux (ORCID: https://orcid.org/0000-0003-1826-2810)
- F. Maillot
- Christian Jacob (ORCID: https://orcid.org/0000-0001-6960-728X)
- Julia Theil
- Claire Douillard (ORCID: https://orcid.org/0000-0002-5714-1600)
- Kim Maren Schneider
Institutions
- Université Claude Bernard Lyon 1 (FR)
- Université de Tours (FR)
- Hôpital Necker-Enfants Malades (FR)
- Inserm (FR)
- Centre Hospitalier Universitaire de Lille (FR)
- Institut National de Recherche pour l'Agriculture, l'Alimentation et l'Environnement (FR)
- Cemka-Eval (France) (FR)
- Assistance Publique – Hôpitaux de Paris (FR)
- Laboratoire de recherche en cardiovasculaire, métabolisme, diabétologie et nutrition (FR)
- Hôpital Louis Pradel (FR)
- Hôpital Claude Huriez (FR)
Publication Details
- Journal
- Molecular Genetics and Metabolism Reports
- Published
- 2024-08-20
- DOI
- https://doi.org/10.1016/j.ymgmr.2024.101134
- Citations
- 1
- Primary Topic
- Metabolism and Genetic Disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.38
Funders
- BioMarin Pharmaceutical